TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸ABSI

Absci Corporation - Common Stock

NASDAQ
$7.51
▼ $1.56 (-17.2%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 20 Nov 2026
H $12.55L $4.49+47.3%
$12.55$10.93$9.32$7.71$6.1$4.49$8.16
RSI (14)
Intraday · 15-minSell-15RSI 39DowntrendMACD Bullishfor day-trading context — not advice

Technical signal

Neutral0
RSI (14)42
oversold 30overbought 70
Trend
Sideways
MACD
Bearish
Bollinger
Within bands
vs 20-day
below
vs 50-day
below
vs 200-day
above
Support
$7.29
Resistance
$12.55
  • Price is below its 50-day average (medium-term weakness).
  • Price is above its 200-day average (long-term uptrend).

Signal backtest · 2026-02-20 → 2026-11-19

Strategy return
+63.5%
Buy & hold
+207.9%
Trades
7
Win rate
29%

$100,000.00 invested would be worth $163,494.17 (+63.5%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Absci Corporation· Biotechnology

source: yahoo

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Sector
Healthcare
Industry
Biotechnology
Employees
140
Headquarters
Vancouver, United States
www.absci.com ↗

Fundamentals

No fundamental data is currently available for this listing from our data providers.

Recent news

News sentiment:▼ Negative0↑ · 1↓ · 7–
  • Absci Stock In Focus After Earnings Report And Commercial Chief Hire— Neutral
    Simply Wall St. · 21 Nov 2026
  • ARKK Is Down, But These 10 Cathie Wood Stocks Have Soared Up to 285% in 2026— Neutral
    Insider Monkey · 18 Nov 2026
  • Absci Corp. (ABSI) Gets Downgraded. Here’s How Much▼ Negative
    Insider Monkey · 17 Nov 2026
  • Absci (ABSI) Advances ABS 201 Plans, Is The 43% Discount Justified?

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

— Neutral
Simply Wall St. · 13 Nov 2026
  • Absci Corp (ABSI) Q3 2026 Earnings Call Highlights: ABS-201 Momentum Builds as Cash Runway ...— Neutral
    GuruFocus.com · 12 Nov 2026
  • Absci Corporation Q3 2026 Earnings Call Summary— Neutral
    Moby · 12 Nov 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.